$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224032355 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$35.00K	$50.00K	$42.00K
YoY Change	-23.91%	19.05%	40.0%
Cost Of Revenue	$8.000K	$8.000K	$0.00
YoY Change	-73.33%		-100.0%
Gross Profit	$27.00K	$42.00K	$42.00K
YoY Change	68.75%	0.0%	-207.69%
Gross Profit Margin	77.14%	84.0%	100.0%
Selling, General & Admin	$3.210M	$2.717M	$2.550M
YoY Change	-40.98%	6.55%	16.92%
% of Gross Profit	11888.89%	6469.05%	6071.43%
Research & Development	$1.437M	$1.145M	$2.953M
YoY Change	-47.44%	-61.23%	19.31%
% of Gross Profit	5322.22%	2726.19%	7030.95%
Depreciation & Amortization	$63.00K	$61.00K	$80.00K
YoY Change	18.87%	-23.75%	175.86%
% of Gross Profit	233.33%	145.24%	190.48%
Operating Expenses	$1.437M	$1.145M	$2.953M
YoY Change	-47.44%	-61.23%	19.31%
Operating Profit	-$4.489M	-$3.694M	-$5.461M
YoY Change	-44.97%	-32.36%	16.32%
Interest Expense	$202.0K	$179.0K
YoY Change	-1362.5%
% of Operating Profit
Other Income/Expense, Net	$718.0K	$2.580M	$318.0K
YoY Change	144.22%	711.32%	10500.0%
Pretax Income	-$3.700M	-$1.836M	-$4.909M
YoY Change	-52.66%	-62.6%	1.2%
Income Tax
% Of Pretax Income
Net Earnings	-$3.700M	-$1.836M	-$4.909M
YoY Change	-52.66%	-62.6%	1.2%
Net Earnings / Revenue	-10571.43%	-3672.0%	-11688.1%
Basic Earnings Per Share	-$0.06	-$0.03	-$0.10
Diluted Earnings Per Share	-$0.06	-$0.03	-$0.10
COMMON SHARES
Basic Shares Outstanding	57.14M shares	51.28M shares	48.41M shares
Diluted Shares Outstanding	57.68M shares	52.84M shares	48.41M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.202M	$10.06M	$28.40M
YoY Change	-67.89%	-64.57%	-32.02%
Cash & Equivalents	$915.0K	$3.554M	$21.04M
Short-Term Investments	$6.287M	$6.507M	$7.360M
Other Short-Term Assets	$368.0K	$300.0K	$438.0K
YoY Change	39.92%	-31.51%	-89.75%
Inventory
Prepaid Expenses
Receivables			$33.00K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$7.570M	$10.36M	$28.87M
YoY Change	-66.71%	-64.11%	-37.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$117.0K	$109.0K	$145.0K
YoY Change	-13.97%	-24.83%	14.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.716M	$2.054M	$1.784M
YoY Change	29.21%	15.13%	-1.49%
Total Long-Term Assets	$6.018M	$5.354M	$4.748M
YoY Change	17.56%	12.76%	-1.88%
TOTAL ASSETS
Total Short-Term Assets	$7.570M	$10.36M	$28.87M
Total Long-Term Assets	$6.018M	$5.354M	$4.748M
Total Assets	$13.59M	$15.72M	$33.62M
YoY Change	-51.23%	-53.25%	-33.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.264M	$5.455M	$2.151M
YoY Change	124.68%	153.6%	202.11%
Accrued Expenses	$1.011M	$799.0K	$528.0K
YoY Change	-41.26%	51.33%	5.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.593M	$2.354M
YoY Change
Total Short-Term Liabilities	$10.10M	$8.842M	$2.885M
YoY Change	114.16%	206.48%	110.89%
LONG-TERM LIABILITIES
Long-Term Debt	$139.0K	$283.0K	$0.00
YoY Change
Other Long-Term Liabilities	$437.0K	$488.0K	$597.0K
YoY Change	-19.52%	-18.26%	-18.89%
Total Long-Term Liabilities	$139.0K	$283.0K	$597.0K
YoY Change	-74.4%	-52.6%	-18.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.10M	$8.842M	$2.885M
Total Long-Term Liabilities	$139.0K	$283.0K	$597.0K
Total Liabilities	$10.68M	$9.613M	$3.482M
YoY Change	103.0%	176.08%	65.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$420.9M	-$417.2M	-$389.1M
YoY Change	6.03%	7.21%	5.23%
Common Stock	$59.00K	$57.00K	$48.00K
YoY Change	22.92%	18.75%	-99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.912M	$6.102M	$30.14M
YoY Change
Total Liabilities & Shareholders Equity	$13.59M	$15.72M	$33.62M
YoY Change	-51.23%	-53.25%	-33.93%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$3.700M	-$1.836M	-$4.909M
YoY Change	-52.66%	-62.6%	1.2%
Depreciation, Depletion And Amortization	$63.00K	$61.00K	$80.00K
YoY Change	18.87%	-23.75%	175.86%
Cash From Operating Activities	-$3.110M	-$3.008M	-$2.158M
YoY Change	-45.16%	39.39%	-6.7%
INVESTING ACTIVITIES
Capital Expenditures	$18.00K		$203.0K
YoY Change	-90.22%		-572.09%
Acquisitions
YoY Change
Other Investing Activities	$352.0K	$826.0K	-$1.000K
YoY Change	-331.58%	-82700.0%	-100.01%
Cash From Investing Activities	$334.0K	$826.0K	-$204.0K
YoY Change	-199.4%	-504.9%	-102.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	137.0K	2.441M	5.000K
YoY Change	-41.2%	48720.0%	-90.91%
NET CHANGE
Cash From Operating Activities	-3.110M	-3.008M	-2.158M
Cash From Investing Activities	334.0K	826.0K	-204.0K
Cash From Financing Activities	137.0K	2.441M	5.000K
Net Change In Cash	-2.639M	259.0K	-2.357M
YoY Change	-54.3%	-110.99%	-143.14%
FREE CASH FLOW
Cash From Operating Activities	-$3.110M	-$3.008M	-$2.158M
Capital Expenditures	$18.00K		$203.0K
Free Cash Flow	-$3.128M		-$2.361M
YoY Change	-46.58%		4.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0000946644
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Manufacturing Costs ManufacturingCosts		usd
	us-gaap	Manufacturing Costs ManufacturingCosts		usd
CY2023Q2	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023Q2	AIM	Gain Loss On Warrant Issuance GainLossOnWarrantIssuance		usd
CY2024Q2	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss		usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss		usd
CY2024Q1	AIM	Stock Issued During Period Value Cashless Exercise Of Warrants StockIssuedDuringPeriodValueCashlessExerciseOfWarrants		usd
CY2024Q1	AIM	Stock Issued During Period Value Committed Shares StockIssuedDuringPeriodValueCommittedShares		usd
CY2024Q2	AIM	Stock Issued During Period Value Preferred Shares Expired StockIssuedDuringPeriodValuePreferredSharesExpired		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss		usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives		usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	AIM	Proceeds From Issuance Of Equity Warrants ProceedsFromIssuanceOfEquityWarrants		usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred		usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet		usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet		usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization		usd
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized		usd
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized		usd
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Loan Processing Fee LoanProcessingFee		usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization		usd
CY2024Q2	AIM	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree		usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57136680	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57136680	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49102484	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49102484	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	57000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	49000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	423206000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	419004000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-417161000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409508000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6102000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10234000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15715000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19381000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90000	usd
CY2024Q2	us-gaap	Revenues Revenues	50000	usd
CY2023Q2	us-gaap	Revenues Revenues	42000	usd
	us-gaap	Revenues Revenues	90000	usd
CY2024Q2	us-gaap	Manufacturing Costs ManufacturingCosts	8000	usd
	us-gaap	Manufacturing Costs ManufacturingCosts	16000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1145000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2953000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3096000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2591000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2550000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6406000	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	3744000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	5503000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	9518000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3694000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5461000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9428000	usd
CY2024Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-85000	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-94000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-177000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2580000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	318000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2661000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	179000	usd
	us-gaap	Interest Expense InterestExpense	251000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-23000	usd
CY2024Q2	AIM	Gain Loss On Warrant Issuance GainLossOnWarrantIssuance	-458000	usd
	AIM	Gain Loss On Warrant Issuance GainLossOnWarrantIssuance	-458000	usd
CY2023Q2	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-328000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-582000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1836000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4909000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7653000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52837477	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52837477	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48411251	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48411251	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51161956	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51161956	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48405675	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48405675	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10234000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	329000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	80000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5817000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4826000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	532000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2500000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	80000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1836000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6102000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3661000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34989000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34989000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4909000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30135000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30135000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7653000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8570000	usd
	us-gaap	Depreciation Depreciation	18000	usd
	us-gaap	Depreciation Depreciation	21000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	101000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	106000	usd
	AIM	Changes In Rou Assets ChangesInRouAssets	150000	usd
	AIM	Changes In Rou Assets ChangesInRouAssets	48000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-582000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	160000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	132000	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-177000	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	109000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-458000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	270000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1181000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1676000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-149000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-34000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	366000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	39000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-988000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1774000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1187000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-278000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7823000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5838000	usd
	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	1105000	usd
	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	598000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	158000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	712000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	35000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	279000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	203000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	668000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-282000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	856000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	105000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2367000	usd
	AIM	Proceeds From Issuance Of Equity Warrants ProceedsFromIssuanceOfEquityWarrants	2047000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5270000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	105000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1885000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6015000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5439000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27053000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3554000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21038000	usd
	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets	3000	usd
	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets	-48000	usd
	AIM	Unrealized Gain Loss On Marketable Investments UnrealizedGainLossOnMarketableInvestments	42000	usd
	AIM	Unrealized Gain Loss On Marketable Investments UnrealizedGainLossOnMarketableInvestments	196000	usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	6000	usd
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	80000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	50000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	160000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	132000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	134000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	85000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	6507000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7631000	usd
CY2024Q2	us-gaap	Marketable Securities MarketableSecurities	6507000	usd
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	6507000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-177000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-218000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	41000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	7631000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	7631000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	109000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-87000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	196000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	414000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	518000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1352000	usd
CY2024Q2	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	154000	usd
CY2023Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	184000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	118000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	799000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1986000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1448000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1448000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1339000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1321000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127000	usd
	us-gaap	Depreciation Depreciation	18000	usd
	us-gaap	Depreciation Depreciation	21000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3455000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-964000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2491000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3176000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-863000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	282000	usd
	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments	3000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	101000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2491000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	136000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	258000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	255000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	230000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	211000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1401000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2491000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.20
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	114	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.80
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q2	AIM	Common Stock Shares With Limitations And Restrictions On Usage CommonStockSharesWithLimitationsAndRestrictionsOnUsage	8000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57136680	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57136680	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49102484	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49102484	shares
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000	usd
CY2020Q1	AIM	Warrant Modifications WarrantModifications	46000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	152160	shares
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2500000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	205000	shares
CY2024Q1	AIM	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Expired ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired	5830028	shares
	AIM	Low Range Of Probability LowRangeOfProbability	0.005	pure
	AIM	Medium Range Of Probability MediumRangeOfProbability	0.010	pure
	AIM	High Range Of Probability HighRangeOfProbability	0.050	pure
	AIM	High Range Of Probability HighRangeOfProbability	0.050	pure
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	3301000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-648000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	16000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2637000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2354000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	283000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	133000	usd
	us-gaap	Interest Costs Incurred InterestCostsIncurred	133000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	133000	usd
	us-gaap	Loan Processing Fee LoanProcessingFee	4000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	137000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1250000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2051000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	3301000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Current Gross DeferredFinanceCostsCurrentGross	2750000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	386000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	10000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	551000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	262000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	6000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	700000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	722000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	718000	usd
CY2024Q2	AIM	Operation Lease Right Of Use Asset Accumulated Amortization OperationLeaseRightOfUseAssetAccumulatedAmortization	352000	usd
CY2023Q4	AIM	Operation Lease Right Of Use Asset Accumulated Amortization OperationLeaseRightOfUseAssetAccumulatedAmortization	363000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	150000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	141000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	124000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	201000	usd
	us-gaap	Lease Cost LeaseCost	274000	usd
	us-gaap	Lease Cost LeaseCost	342000	usd
	us-gaap	Lease Cost LeaseCost	274000	usd
	us-gaap	Lease Cost LeaseCost	342000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P35M
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P41M
CY2024Q2	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.10	pure
CY2023Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.10	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	153000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	273000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	244000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	159000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	107000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	722000	usd

Files In Submission

Name	View Source	Status
aim-20240630_cal.xml	Edgar Link	unprocessable
0001493152-24-032355-index-headers.html	Edgar Link	pending
0001493152-24-032355-index.html	Edgar Link	pending
0001493152-24-032355.txt	Edgar Link	pending
0001493152-24-032355-xbrl.zip	Edgar Link	pending
aim-20240630.xsd	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
aim-20240630_def.xml	Edgar Link	unprocessable
aim-20240630_lab.xml	Edgar Link	unprocessable
aim-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2024 Q3 Form 10-Q Financial Statement

#000149315224032355 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2024 Q3 Form 10-Q Financial Statement

#000149315224032355 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim